Articles tagged with Breast Cancer Cells
A unique nano-scaled DNA signature common to all cancers has been discovered, allowing for rapid detection from various tissues. This breakthrough technology uses gold nanoparticles to detect cancer DNA fragments and could lead to point-of-care diagnostics.
Scientists have developed a new system to rapidly and accurately detect tumor margins during breast cancer surgery, using a 'click-to-sense' acrolein probe that conjugates with live breast cancer cells. The method has been shown to be highly sensitive and selective, with a 97% accuracy rate.
Researchers found that breast tumors can recruit bone marrow-derived fibroblasts to boost growth and metastasis. These cells lack key signaling proteins and produce clusterin, promoting blood vessel formation and tumor progression.
A research team at Hokkaido University found that lower TRIM29 levels correlate with more mobile and invasive squamous cell carcinoma cells, leading to a worse prognosis. The TRIM-29/keratin interaction plays a crucial role in regulating cell shape and motility.
Cancer cells exhibit sneaky movement patterns that allow them to invade adjacent tissue and spread throughout the body. Researchers have found a way to target these movements, using medicines to stop cancer cells in their tracks.
Johns Hopkins researchers discovered that blocking the activin receptor can suppress the growth and spread of retinoblastoma cells, halting the cancer's progression. The therapy showed promising results in both human cells and zebra fish, offering new hope for treating this deadly eye cancer in children.
Researchers found that failing DNA repair systems lead to chromosome fragmentation and defective assembly in cancer cells. This can be treated with PARP inhibitors, which block another critical DNA repair enzyme, causing genetic damage that kills the cell.
Scientists at EPFL have found that half of luminal epithelial breast cells express estrogen receptor at low levels, affecting cell function and cancer development. The estrogen receptor plays a biphasic role in breast cell growth and inhibition during pregnancy.
Researchers have discovered that metastatic cancer cells follow a Lévy walk movement pattern, like sharks searching for food, which aids in their rapid spread and direction. The team was able to reprogram this behavior using chemical inhibitors, changing it back to more typical diffusive motion
Researchers have discovered how engineered protein receptor CAR activates cancer-fighting cells, shedding light on effective treatments and side effects. By understanding phosphorylation processes, they aim to design better cancer-fighting CARs with fewer side effects.
Breast cancer cells can become invasive by changing their identity through a process called epithelial-mesenchymal transition (EMT). A newly identified protein, CXADR, plays a crucial role in this process. Reintroducing CXADR into breast cancer cells can change their behavior and repress invasive properties.
A team of scientists has identified a key protein that triggers the activation of mammary stem cells during puberty, leading to the rapid expansion of the mammary gland. FoxP1 plays a crucial role in switching off proteins that keep mammary stem cells dormant, allowing them to divide and drive growth.
Researchers at York University discovered a new role for beta-catenin, a protein involved in cell regulation, in controlling messenger RNA translation. This finding could lead to the development of novel therapeutic interventions for cancers and neurological diseases.
A diet high in omega-3 fatty acids from fish oil may delay the development and spread of breast cancer cells in mice. The study found that these cells took significantly longer to form tumors and grew smaller over time.
Day's research develops layer-by-layer assembled nanoshells to deliver tumor suppressor miR-34a into cells, reducing cancer cell growth. Gleghorn discovers TRPV4 regulates airway development in fetal lungs, potentially leading to new therapeutic targets for bronchopulmonary dysplasia.
A study published in Cell Death Discovery found that a critical switch during breaks in nursing controls whether breast cells survive or die, potentially providing a strategy to block cancer. The researchers identified the unfolded protein response (UPR) pathway as a key player in this process.
Researchers at the University of Bradford have developed a universal blood test that can detect cancer in patients under suspicion of the disease with high accuracy. The test measures DNA damage caused by ultraviolet light and uses Artificial Intelligence to analyze thousands of cells, improving predictability beyond 93%.
A new report reveals a protein, deltaNp63, that directs myeloid-derived immunosuppressor cells (MDSCs) to the primary tumor and metastatic sites, promoting tumor growth and metastasis. Blocking deltaNp63 or MDSCs reduced tumor growth and metastasis in a mouse model of triple-negative breast cancer.
A commonly-used anti-psychotic drug has shown promise in treating aggressive triple negative breast cancer by inhibiting the growth and spread of cancer cells. The study found that up to 90% of cancer cells died following treatment with Pimozide, reducing tumour size and metastases.
Researchers have developed a novel T cell bispecific antibody that guides immune cells to HER2-positive breast cancer cells, offering a targeted and safe approach. The therapy has shown promise in tackling certain breast cancers by exclusively targeting cancerous cells.
Aggressive breast cancer cells exploit the natural stress protector heat shock protein 70 (HSP70) to thrive and evade cell death, says a new study. The finding highlights how cancer cells manipulate tumor necrosis factor alpha (TNFα), which normally promotes self-destruction, to aid their survival.
Researchers at Cold Spring Harbor Laboratory found that sustained lung inflammation can awaken dormant breast and prostate cancer cells, leading to metastasis. A new antibody approach may block this signaling pathway, preventing cancer recurrence.
Researchers create 3D models of breast cancer tumors using stromal cells, which play a major role in cancer growth and progression. The study aims to introduce stromal cells as new therapeutic targets, offering potential treatments for triple-negative breast cancer.
Scientists at the Medical University of South Carolina discovered that over-expression of VRK1 actually slows down cancer cell migration and invasion, but enables cells to form colonies under 3D conditions. High levels of VRK1 are associated with aggressive breast cancers and poor prognoses in patients with metastatic breast cancer.
Scientists at St. Jude Children's Research Hospital have discovered a connection between the process that causes oil and vinegar to separate in salad dressing and solid tumors like prostate and breast cancer. The study found mutations in the tumor suppressor gene SPOP contribute to cancer by disrupting liquid-liquid phase separation, l...
Researchers at Hokkaido University identified a pathway that facilitates the dispersion of mitochondria towards the cell periphery, increasing cancer invasiveness. Blocking this pathway led to the aggregation of mitochondria and an increase in reactive oxygen species production, resulting in cancer cell death.
Researchers found that acute changes in extracellular matrix components can trigger rapid changes in cell metabolism and migration, potentially leading to cancer metastasis. The study suggests targeting tumor metabolism by altering the extracellular matrix could lead to new cancer treatments.
A team at the Salk Institute has identified a genetic master switch, Sox10, that controls the growth and invasion of aggressive triple-negative breast cancers. This discovery may lead to new avenues for diagnosing and treating intractable cancers by targeting specific genes.
Researchers have discovered a specific protein, FABP5, that promotes processes associated with cancer aggressiveness, including cell growth, invasiveness, survival, and inflammation. Understanding the molecular pathways of this protein could lead to finding more effective therapeutic targets for prostate and breast cancers.
Researchers used advanced cryo-EM technology to determine the structure of a molecular complex implicated in birth defects and several cancers. The study revealed that two Patched-1 molecules simultaneously engage a single Hedgehog molecule, forming a unique 2-to-1 ratio PTCH1-HH complex required for efficient Hedgehog signaling.
A study published in Cell found that cells in a three-dimensional environment divide chromosomes correctly, while those in a two-dimensional environment make mistakes. This discovery could help explain why chromosome errors are common in cancerous cells.
Research reveals key physical properties of giant cancer cells, including stiffness and ability to move further than standard cancer cells. This understanding may lead to the development of targeted treatments.
Researchers have identified a potential new treatment for aggressive breast cancer by targeting the communication channel between non-cancerous cells and tumour cells. The study, published in Nature Communications, shows that disrupting this connection can slow tumour growth, increase sensitivity to chemotherapy and improve survival.
Researchers at Stanford University School of Medicine found that individuals with six or more basal cell carcinomas over a 10-year period are three times more likely to develop other, unrelated cancers. The study suggests that mutations in DNA-damage-repair proteins may be linked to increased cancer susceptibility.
Researchers at Salk Institute identify genetic features of human basal-like breast cancers that share similarities with embryonic mammary stem cells, which may be targeted therapeutically. The study provides insights into how cancer cells gain plasticity and become resistant to therapies.
Scientists at Huntsman Cancer Institute have generated a comprehensive molecular map of genes that control breast tissue formation, providing new insights into the development of breast cancer. The study identifies hundreds of potentially critical genes for further research as regulators of normal and cancerous development.
Researchers found that PTEN loss in normal breast tissue cells can lead to increased genetic instability and reduced response to radiation therapy. The discovery suggests that targeting stromal cells with low PTEN may help predict which patients are more likely to benefit from radiation treatment.
Researchers have found that the cell layer surrounding breast milk ducts acts as an active defense mechanism to prevent cancer cells from spreading, grabbing stray cells and pulling them back in up to 92% of the time. This discovery challenges previous assumptions about the myoepithelial layer's role in cancer invasion.
Scientists at Scripps Research discovered that inhibiting Rad52 can target and kill tumors with a deficient gene, such as triple-negative breast cancers. This approach exploits synthetic lethality, where cells with both defects die, reducing side effects and toxicity.
A study reveals that blocking heat shock transcription factor 1 (HSF1) signaling in T cell acute lymphoblastic leukemia (T-ALL) could represent a new approach in treating the aggressive disease. The discovery identifies a subset of T-ALL patients most likely to benefit from a new therapy.
Scientists at Cold Spring Harbor Laboratory have published a detailed map of structural variations in breast cancer cells, revealing 20,000 genetic errors that disrupt cell growth and cause cancer's hallmark. The study sheds light on how cancer cells rapidly evolve and provides valuable insights for future research and clinical practice.
Researchers at Brigham and Women's Hospital have developed engineered cancer cells that can home in on and destroy tumors using CRISPR technology. The treatment shows promise in preclinical models across multiple types of cancer, establishing a potential roadmap for clinical translation.
Researchers at the University of Zurich have developed a new method to quickly test various anti-cancer drugs and treatment combinations at the cellular level. The approach has revealed how PARP inhibitors work in cancer cells by locking their target protein in an inactive state, leading to DNA damage and cell death.
Researchers at Georgia State University and Vanderbilt University Medical Center have identified xCT, an amino acid transporter, as a potential therapeutic target for non-small cell lung cancer. The study found that inhibiting xCT using sulfasalazine reduced tumor formation in laboratory tests and improved survival rates in mice.
Deb Kelly, a Virginia Tech researcher, has received $2.1 million from the National Cancer Institute to investigate the BRCA1 protein's role in breast cancer. Her team aims to develop new tools and techniques to better detect, prevent, and repair mutations found in cancers related to BRCA1.
Researchers reveal curcumin binds to and inhibits DYRK2, impairing cell proliferation and reducing cancer burden. Curcumin's effectiveness may be limited due to its rapid expulsion from the body.
Researchers discovered a novel mechanism of estrogen receptor signaling regulated by fibronectin, which boosts cancer cell growth and survival. Fibronectin prolongs the activity of estrogen receptors in breast cancer cells, allowing them to become resistant to common endocrine therapy drugs.
Researchers found that hSATa satellite RNA directly interferes with DNA copying and damage repair in cells, leading to breast cancer. This discovery suggests targeting satellite RNAs could provide another approach for treating various cancers, including breast, ovarian, prostate, and pancreatic cancer.
Research reveals epigenetic factors, including EZH2 protein, play a crucial role in melanoma formation. The loss of cilia in pigment cells activates carcinogenic signaling pathways, leading to aggressive melanoma.
A new computational method, MACHINA, has been developed to track the spread of cancer cells from one part of the body to another. The algorithm integrates DNA sequence data with information on where cells are located in the body, yielding a clearer picture of cancer migration histories than previous studies.
A new regulatory axis involving the transcription factor Prox1 has been revealed to negatively regulate MMP14 protein levels, which plays a significant role in cancer progression and metastasis. This discovery provides new insights into the mechanisms governing MMP14's function in physiological processes such as wound healing.
Researchers found that resveratrol inhibits mutant p53 protein aggregation, preventing breast cancer cell migration and proliferation. This breakthrough could lead to a treatment for over half of malignant tumors, targeting novel strategic targets in cancer research.
Researchers discovered that oxygen-starved tumor cells struggle to produce aspartate, a crucial amino acid. By targeting this Achilles' heel, doctors may develop new treatments to block aspartate uptake or production.
Researchers at the University of Wisconsin-Madison have identified a protein called Munc13-4 that helps cancer cells secrete exosomes, stimulating tumor growth. Exosome release is dependent on calcium levels and can transfer oncogenes to neighboring cells, contributing to tumor progression.
Researchers at Princess Margaret Cancer Centre discovered that epigenetic proteins promote mammary gland stem cell proliferation in response to progesterone. Inhibiting these proteins with drugs could potentially prevent breast cancer development in women at high risk of the disease.
Researchers from eight labs employed six different technologies to measure cell stiffness, bending, and viscosity. The study aimed to compare techniques and identify key differences for future diagnostic applications.
The study reveals the discovery of three new distinct epithelial cell populations, including L1- and L2-type luminal cells, which can aid in understanding the origins of breast cancer. The researchers used single-cell mRNA sequencing to create a high-resolution molecular census of human breast epithelial cells.
Scientists have engineered new anti-cancer antibodies that attract killer T cells directly to cancer cells covered with the ROR1 protein. These bi-specific antibodies can target several types of cancer and work for about five days, outlasting current approaches.
Researchers have developed a novel RNA-modifying tool called RIBOTAC, which uses a small-molecule-based approach to selectively delete toxic gene products and control the body's defense mechanisms. This technology has potential applications for treating genetic diseases such as cancer and incurable human genetic disorders.
Triple-negative breast cancer patients have fewer effective treatments due to high levels of immune suppressor cells. Researchers identified a metabolic pathway linking glycolysis and C/EBP-beta expression, which supports suppressor cell growth and reduces patient outcomes.